伊利倫 (NYSE: LLY) 股票正在徘徊在 $900 關口附近，將公司列入高價股，常引發拆分猜測。

While a split does not change the fundamentals of the underlying business, it makes the stock more liquid and increases its appeal to a wider investor base. Stock splits often reflect management's confidence in the company's sustained long-term growth. That's exactly what makes 伊利倫 stand out today.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an Indispensable Monopoly providing the critical technology Nvidia and Intel both need. Continue

Image source: Getty Images.

Eli Lilly has emerged as a dominant force in obesity and metabolic health. Its incretin‑based (GLP‑1) drugs, Mounjaro and Zepbound, are seeing a solid rise in patient volumes, with growth increasingly driven by demand rather than pricing. Mounjaro 的營收年增 99% 至近 $23 billion，而 Zepbound 的營收年增 175% 至約 $13.5 billion.

Despite strong adoption, GLP‑1 drug penetration remains in the mid‑single digits among the eligible obesity population in the U.S. This suggests significant room for Eli Lilly's obesity portfolio to grow in the future. The obesity market may expand even further, as the company prepares to launch oral GLP‑1 therapy orfoglutide, which could bring in patients who have so far avoided injectable treatments.

In fiscal 2025, Eli Lilly's total revenue surged 45% year over year to roughly $65.2 billion, while earnings per share rose 86% year over year to $24.2. The company is guiding for fiscal 2026 revenue in the range of $80 billion to $83 billion. While management expects pricing of its key products to drag revenue growth by low‑ to mid‑teens percentage, volume growth is set to more than offset it. This highlights that the demand for Eli Lilly's drugs is both broad‑based and durable.

Eli Lilly has committed over $55 billion toward manufacturing expansion since 2020. The company is also advancing 36 active late‑stage phase 3 programs. Considering the stock's price appreciation and the company's impressive revenue tailwinds, Eli Lilly seems well‑positioned for a potential stock split in 2026.

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

分析師觀點

以我多年的市場經驗來看，投資者在審視伊利倫時，除了關注其高價與潛在拆分外，更應聚焦於其在肥胖藥物領域的持續創新與擴張。公司在研發管線與製造擴建上的重大投資，顯示出長期成長的強烈信心。因此，若市場對其產品需求如預期持續，股價在未來一年內仍具上行空間，值得關注。